Genprex to Showcase Oncology and Diabetes Programs at H.C.…

Event summary

Genprex to present at H.C. Wainwright conference on September 14, 2026, detailing its lead oncology and preclinical diabetes programs.
CEO Ryan Confer to discuss Reqorsa® Gene Therapy and development priorities for both programs.
Chief Medical Officer Mark Berger, MD, and SVP of Intellectual Property Thomas Gallagher to participate in investor meetings.
Reqorsa® has Fast Track and Orphan Drug designations from the FDA for lung cancer programs.
Diabetes program aims to restore insulin-producing function in Type 1 and Type 2 diabetes.

The big picture

Genprex's participation in the H.C. Wainwright conference underscores its dual focus on oncology and diabetes, areas with significant unmet medical needs. The company's strategic emphasis on gene therapy aligns with broader industry trends toward targeted, non-viral treatments. Success in these programs could position Genprex as a key player in both cancer and metabolic disease therapeutics.

What we're watching

Clinical Progress: How the Acclaim-1 and Acclaim-3 trials for lung cancer will advance under Fast Track designation.
Diabetes Pipeline: Whether the preclinical diabetes program can transition smoothly into IND-enabling studies.
Investor Sentiment: The impact of conference presentations on Genprex's valuation and investor confidence.